BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Telik, Inc. (TELK) Announces Second Quarter 2012 Financial Results


8/13/2012 9:50:00 AM

PALO ALTO, Calif., Aug. 10, 2012 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today reported a net loss of $2.1 million, or $1.11 per share, for the second quarter ended June 30, 2012, compared with a net loss of $3.0 million, or $1.67 per share (adjusted for the 1-for-30 reverse split of the company's common stock effected on March 30, 2012), for the comparable period in 2011.

For the quarter ended June 30, 2012, total operating costs and expenses were $2.1 million, compared with $3.0 million in the 2011 second quarter. Operating expenses in the 2012 second quarter included stock-based compensation expense of approximately $0.2 million. Operating expenses were approximately 32% lower in the second quarter of 2012 compared with the same period in 2011, primarily due to lower headcount, lower stock-based compensation expense and lower corporate administrative costs.

For the six months ended June 30, 2012, Telik reported a net loss of $4.3 million, or $2.36 per share, compared with a net loss of $6.7 million, or $3.72 per share (adjusted for the 1-for-30 reverse stock split), for the six months ended June 30, 2011. Total operating expenses for the first six months of 2012 were $4.3 million, compared with $6.7 million for the first six months of 2011. Operating expenses in the first six months of 2012 included approximately $0.4 million in stock-based compensation expense. The reduction in operating expenses of approximately 35% in the first six months of 2012 compared with the same period in 2011 was primarily due to lower headcount and stock-based compensation expenses, lower clinical development and related costs, and lower corporate expenses.

At June 30, 2012, Telik had $8.1 million in cash, cash equivalents and investments including restricted investments, compared to $11.7 million at December 31, 2011. In order to meet its cash requirements beyond 2012, the company will have to raise additional funds through corporate partnering or equity financings. Although the company has been able to raise funds through its At Market Issuance Sales Agreement, there is no assurance Telik will be successful in obtaining additional funding in the future.

About Telik

Telik, Inc. of Palo Alto, CA is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic disorders including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.

TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.

Telik, Inc.

Statements of Operations

(In thousands, except per share amounts)

(Unaudited)
























Three Months Ended


Six Months Ended




June 30,


June 30,




2012


2011


2012


2011











Operating costs and expenses:









Research and development

$ 932


$ 1,465


$ 1,921


$ 3,159


General and administrative

1,123


1,546


2,412


3,540



Total operating costs and expenses

2,055


3,011


4,333


6,699











Loss from operations

(2,055)


(3,011)


(4,333)


(6,699)











Interest and other income (expense), net

3


10


4


24

Net loss

Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->